Indomethacin Treatment of Acute Experimental Pancreatitis in the Rat

Lankisch, P. G.; Koop, H.; Winckler, K.; Kunze, H.; Vogt, Walter

doi:10.3109/00365527809181774

Cited by 49 publications

(28 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, animal experiments failed to show a beneficial effect of glucagon in acute pancreatitis in rats (Lankisch et al, 1974;Fodor et al, 1975) and dogs (Condon et al, 1974). In controlled studies in man neither glucagon (Durr et al, 1976) nor calcitonin (Goebell, 1976) significantly influenced the course of acute pancreatitis.…”

Section: Discussionmentioning

confidence: 99%

“…Histologically, the degree of necrosis, oedema, and leucocyte infiltration was estimated as absent (0), slight (1), moderate (2), and severe (3) as reported before (Lankisch et al, 1974). The remaining pancreas was used for enzyme assays: ot-amylase (EC321 1) according to Rick and Stegbauer (1970) Ascites (ml) 4-3 ± 1 9 57 2-2 6-3 ± 1 9 56 2-7 4-2 ± 2-1* 6-8 1-3 Necrosis 2-4 2-6 2-2 2-2 3-0 2-6 oedema 2-4 2-3 2-7 2-8 2-8 2-6 leucocyte infiltration 1-2 1.1 0-7 0-6 12; controls n = 11; 0-0 2-5% Na-taurocholatepancreatitis; SRIF-treatment n = 12; controls n = 10;…”

Section: Methodsmentioning

confidence: 99%

“…Acute experimental pancreatitis was induced by retrograde injection of 0-6 ml of 0-8, 2-0, 2-5, and 3-0 Na-taurocholate (Serva Feinbiochemica, Heidelberg) into the pancreatic ducts of 101 male Wistar rats (180-220 g) (Lankisch et al, 1974). Linear SRIF (Serono, Freiburg) was given subcutaneously at a dosage of 200 ,ug during operation as a bolus injection followed by infusion of 100 ,ug/100 g body weight/h for three hours.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Somatostatin therapy of acute experimental pancreatitis.

Lankisch¹,

Koop²,

Winckler³

et al. 1977

Gut

View full text Add to dashboard Cite

SUMMARY Because somatostatin (SRIF) reduces exocrine pancreatic secretion, its effect on acute pancreatitis was investigated in rats. Linear SRIF reduced serum amylase and lipase but had no effect on pancreatic necrosis, oedema, leucocyte infiltration, and enzyme content. The mortality rate was not reduced. These results do not recommend the use of SRIF in the treatment of acute pancreatitis.Cyclic somatostatin (SRIF) significantly reduces hormonal Dollinger et al., 1976;Domschke et al., 1976) and non-hormonal stimulated pancreatic volume and enzyme secretion in man. Linear SRIF inhibits basal and hormonal stimulated enzyme secretion in the rat (Folsch et al., 1976). As 'rest to the gland' is generally considered to be a major aim in the treatment of acute pancreatitis (Trapnell, 1972) the effect of SRIF was investigated in acute experimental pancreatitis in the rat. MethodsAcute experimental pancreatitis was induced by retrograde injection of 0-6 ml of 0-8, 2-0, 2-5, and 3-0 Na-taurocholate (Serva Feinbiochemica, Heidelberg) into the pancreatic ducts of 101 male Wistar rats (180-220 g) (Lankisch et al., 1974). Linear SRIF (Serono, Freiburg) was given subcutaneously at a dosage of 200 ,ug during operation as a bolus injection followed by infusion of 100 ,ug/100 g body weight/h for three hours. This regime had been found to decrease significantly pancreatic enzyme secretion for more than four hours (Folsch et al., 1976). Controls received saline infusions. To investigate the SRIF influence upon the survival rate the following groups were formed (Figure) : (a) SRIFtherapy: n = 6; (b) controls: n = 5; 0-8 %-Na-taurocholate-pancreatitis was not used for survival experiments as the mortality rate of this model is too low to demonstrate the success of a treatment.To study the effects of SRIF upon morphological and enzymatic factors rats were killed four hours after induction of pancreatitis by 0-8, 2-0, and 3 0%-Na-taurocholate-that is, one hour after the treatment was stopped. 2 5%-Na-taurocholate-pancreatitis was not used as there were no distinct differences between 2-0 and 3 0 %-Na-taurocholate-pancreatitis where the above mentioned factors were concerned (Table). Ascites was measured and tissue from the head and the tail of the pancreas was fixed in Bouin's solution, embedded in paraffin, cut in 5 ,um sections, and stained with haematoxylin and eosin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Somatostatin therapy of acute experimental pancreatitis.

Lankisch¹,

Koop²,

Winckler³

et al. 1977

Gut

View full text Add to dashboard Cite

show abstract

“…In experimental acute pancreatitis models, indomethacin was shown to attenuate the severity and lower the mortality (4)(5)(6). Other studies undertaken around the same time, however, showed no beneficial effect (7)(8).…”

Section: Introductionmentioning

confidence: 99%

Rectal indomethacin for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials

Shi¹,

Deng²,

Altaf³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: This meta-analysis was undertaken to evaluate the effect of rectal indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Materials and Methods: Major databases including Embase, Medline, Science Citation Index Expanded, Pubmed and the Cochrane Central Register of Controlled Trials, were searched to identify all relevant studies from January 1960 to July 2013. Randomized controlled trials (RCTs) comparing prophylactic use of rectal indomethacin versus placebo were included. Risk ratio (RR) with 95% confidence interval (CI) was calculated using fixed-or randomeffect models. Results: Three studies met the inclusion criteria and were included in the final analyses. The overall incidence of post-ERCP pancreatitis (PEP) was significantly decreased by prophylactic rectal indomethacin compared with the placebo (RR=0.51; 95% CI=0.37-0.70). The pooled incidence of moderate to severe pancreatitis was also decreased by rectal indomethacin prophylaxis (RR=0.43; 95% CI=0.23-0.80). Conclusion: Rectal indomethacin can reduce the overall incidence and the severity of PEP.

show abstract

“…However, in laboratory-induced AP in rats, it was demonstrated that long-term aspirin pre-treatment reduced the level of serum inflammatory markers and histological severity of inflammation of pancreatic cells [5]. Another previous study in rats found that indomethacin (a NSAID) administration shortly before and after the onset of AP reduced the severity [10]. In vitro, indomethacin showed effective inhibition of the inflammatory enzyme phospholipase-A2 from AP patients serum [11].…”

Section: Introductionmentioning

confidence: 99%

Is Prior Aspirin Use Associated with Reduced Severity in Patients with Acute Pancreatitis?

Lim¹,

Iyengar²,

Terry³

et al. 2017

ujph

View full text Add to dashboard Cite

Clinical severity of Acute Pancreatitis (AP)following the use of Aspirin is inconclusive in previous studies. This study investigated predicting the severity of AP using Ranson criteria at admission and at 48 hours and, the length of hospital stay by prior aspirin use. Medical records of first-presentation AP patients during the five years between 2010 and 2015 were examined in the Goulburn Valley Base Hospital, Victoria, Australia. Uses of aspirin at admission with some co-morbidity, Ranson criteria at admission and at 48 hours, duration of hospital stay including other information were collected. A total of 245 AP medical records were reviewed, of them, 178 used and 67 did not use aspirin prior attending to the hospital. In simple regression analysis, Ranson score was 60% higher at admission (P< 0.001) and 64% higher at 48 hours (P <0.01) among aspirin users compared to non-aspirin users. These findings remained statistically significant after adjusting for other potential indicators. Aspirin use was also found associated with a longer hospital stay both in the unadjusted and adjusted analysis (P<0.01). Further studies using revised Atlanta classification instead of Ranson scoring for the diagnosis of AP severity in aspirin users are critical for clinical guidance.

show abstract

Indomethacin Treatment of Acute Experimental Pancreatitis in the Rat

Cited by 49 publications

References 9 publications

Somatostatin therapy of acute experimental pancreatitis.

Somatostatin therapy of acute experimental pancreatitis.

Rectal indomethacin for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials

Is Prior Aspirin Use Associated with Reduced Severity in Patients with Acute Pancreatitis?

Contact Info

Product

Resources

About